Page last updated: 2024-08-25

sofosbuvir and Genetic Predisposition

sofosbuvir has been researched along with Genetic Predisposition in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Al-Tawashi, AS; Alaa, AM; Awwad, MA; El-Derany, MO; Eltobgy, MM; Gharib, MM; Kasem, MH; Mostafa, AM; Moubarak, AS; Omar, HM; Saafan, HA1
Khan, AJ; Mohindra, S; Negi, TS; Parmar, D; Ranjan, P; Saraswat, VA1
Bon, D; Herrmann, E; Kottilil, S; Masur, H; Meissner, EG; O'Brien, TR; Osinusi, A; Prokunina-Olsson, L; Tang, W1

Trials

1 trial(s) available for sofosbuvir and Genetic Predisposition

ArticleYear
IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
    The Journal of infectious diseases, 2014, Jun-01, Volume: 209, Issue:11

    Topics: Antiviral Agents; Gene Expression Regulation; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014

Other Studies

2 other study(ies) available for sofosbuvir and Genetic Predisposition

ArticleYear
Interleukin-17 haplotyping predicts hepatocellular carcinoma in sofosbuvir, pegylated interferon-alpha-2a & ribavirin treated chronic hepatitis C patients.
    Virus research, 2021, 01-15, Volume: 292

    Topics: alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Haplotypes; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-17; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Receptors, Interleukin-17; Recombinant Proteins; Ribavirin; Sofosbuvir

2021
Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
    Journal of medical virology, 2019, Volume: 91, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Male; Middle Aged; Pyrrolidines; Recurrence; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2019